Early Immune and Synaptic Changes in Parkinson’s Disease Discovered
Parkinson’s disease is recognized as the second most prevalent neurodegenerative disorder globally. A hallmark of this condition is the presence of Lewy bodies, which are aggregations of the protein alpha-synuclein in the brain. Historically, these bodies have been considered the primary culprits behind the degeneration of dopaminergic neurons. However, a new study published in Nature Communications by a research team from LMU Munich and the German Center for Neurodegenerative Diseases (DZNE) offers a more nuanced understanding of this disorder.
Unraveling the Complexity of Lewy Pathology
The researchers analyzed human brain tissue from various stages of Parkinson’s disease, contrasting it with tissue from Alzheimer’s patients, both with and without Lewy pathology. They focused particularly on dopaminergic neurons, which are crucial for motor functions, motivation, reward processing, and cognition.
The analysis revealed a significant correlation between the amount of misfolded alpha-synuclein and the loss of dopaminergic neurons in classic cases of Parkinson’s disease. Interestingly, this correlation was not observed in Alzheimer’s patients with additional Lewy pathology. Despite similar deposits of alpha-synuclein, these patients did not experience neuronal loss, indicating that Lewy pathology cannot solely explain neurodegeneration. Instead, the context of the disease appears to be pivotal in determining whether alpha-synuclein is actually neurotoxic.
Implications of Early Changes in the Disease Process
One of the most striking findings from this study is the demonstration that changes begin long before the loss of neurons occurs. The researchers observed significant synaptic alterations in individuals diagnosed with incidental Lewy body disease, considered a precursor to Parkinson’s disease. Even before the classic Lewy bodies can be identified in the substantia nigra, early immune responses, including the activation of the complement system and selective loss of inhibitory synapses, were evident.
These results suggest an early immunologically mediated remodeling of neuronal networks, laying the groundwork for later Lewy pathology and neuronal degeneration.
Potential for New Biomarkers and Therapeutic Strategies
This study provides insights into previously unknown early disease mechanisms. The immune response and synaptic remodeling processes could serve as novel biomarkers for early detection of Parkinson’s disease, even at precursor stages. Moreover, they introduce new therapeutic avenues that do not solely target alpha-synuclein but rather early inflammatory and synaptic processes.
“If we can influence these early changes in a targeted manner, there is a chance to slow down the disease process significantly—possibly even before irreversible neuronal loss occurs,” states Dr. Thomas Köglsperger, the study’s lead researcher from the Neurological Clinic and Polyclinic at LMU Munich.
Methodology: Advanced Techniques for a Deeper Understanding
The researchers employed a combination of spatial transcriptomics, spatial proteomics, and alpha-synuclein seeding assays on human post-mortem brain tissue. This multifaceted approach enabled them to investigate molecular changes with unprecedented spatial resolution, uncovering new mechanisms related to the onset of Parkinson’s disease.
As research continues to delve into the complexities of Parkinson’s disease, the findings from this study may pave the way for innovative screening methods and interventions aimed at addressing the condition much earlier in its course.
Contact for Scientific Inquiries:
PD Dr. med. Thomas Köglsperger
Head of the Deep Brain Stimulation & Pump Therapy Outpatient Clinic
Neurological Clinic and Polyclinic
LMU Klinikum Munich, Campus Großhadern
Tel: +49 89 4400-73901
E-Mail: [email protected]
For further information, readers can access the full study in Nature Communications.
